Synonyms: DB-289 | DB289
Compound class:
Synthetic organic
Comment: Pafuramidine (DB-289) is a prodrug which generates the active moiety DB-75 which exhibits antiprotozoal and antifungal activities [1]. It is a pentamidine-related dicationic molecule. Mechanistically, the drug binds to the minor groove of DNA. It has activity against parasites and also Mycobacterium tuberculosis.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Pafuramidine was advanced to clinical trials but not for bacterial infections. Phase 1 trials demonstrated safety in humans. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00803933 | Trial of DB289 for the Treatment of Stage I African Trypanosomiasis | Phase 2 Interventional | Immtech Pharmaceuticals, Inc | ||
NCT00302341 | DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) | Phase 3 Interventional | Immtech Pharmaceuticals, Inc | This trial was put on hold by the FDA in 2007, due to safety concerns, and was subsequently terminated. | |
NCT00408369 | Prophylactic Antimalarial Activity of DB289 in Volunteers | Phase 1/Phase 2 Interventional | Immtech Pharmaceuticals, Inc | 2 |